Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Eur Urol. 2018 Nov 7;75(2):242–250. doi: 10.1016/j.eururo.2018.10.040

Fig. 5.

Fig. 5

Platinum-treated bladder cancer patients with low levels of MSH2 protein correlate with poorer survival. Survival of patients was compared with MSH2 RPPA level in 340 bladder cancer patients. Overall survival is plotted for bladder cancer patients with a (A) platinum-based treatment or (B) nonpharmacologic or radiation treatment. Survival of patients with low MSH2 (red) is compared with those with medium or high levels of mSh2 (purple). The statistical difference in survival was calculated using a log-rank test. med = medium; RPPA = reverse-phase protein array.